Mycophenolate mofetil in paediatric autoimmune or immune-mediated diseases of the central nervous system: clinical experience and recommendations.
Margherita NosadiniJonathan GadianMing LimStefano SartoriTerrence ThomasRussell C DalePublished in: Developmental medicine and child neurology (2018)
Mycophenolate mofetil (MMF) use was heterogeneous with relatively common adverse events, although mostly not severe. MMF treatment reduced median annualized relapse rate, although 20% of patients relapsed on MMF. A high relapse rate pre-MMF and late MMF start were associated with higher probability of relapsing on MMF. Most relapses were associated with suboptimal MMF dosage, short MMF duration, or concurrent medication weaning/discontinuation.
Keyphrases
- multiple sclerosis
- end stage renal disease
- newly diagnosed
- emergency department
- acute lymphoblastic leukemia
- intensive care unit
- chronic kidney disease
- ejection fraction
- acute myeloid leukemia
- peritoneal dialysis
- diffuse large b cell lymphoma
- clinical practice
- multiple myeloma
- free survival
- hodgkin lymphoma
- adverse drug
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome